July 14, 2008 - AngioDynamics (NASDAQ:ANGO) announced results from its RAPTURE study, which was conducted to identify the feasibility, efficacy and safety of percutaneous radiofrequency ablation (RFA) of malignant lung tumors. Published in The Lancet Oncology July 2008 issue, the results show a high proportion of sustained, complete tumor response after treatment with RFA. This prospective, intention-to-treat clinical trial enrolled 106 patients with 183 lung tumors that were 3.5 cm in diameter or smaller (mean 1.7 cm) at seven centers in the United States, Europe, and Australia. Diagnoses included non-small-cell lung cancer (NSCLC) in 33 patients, metastasis from colorectal carcinoma in 53 patients, and metastasis from other primary malignancies in 20 patients. Patients underwent radiofrequency ablation in accordance with standard rules for CT-guided lung biopsy and were then followed for a minimum of 2 years. All patients were considered by their treating physician to be unsuitable for surgery, radiotherapy or chemotherapy... AngioDynamics' Press Release -
